Updated:Trade Call Opinion: $TSRX For a Bounce Back Over $8

Updated:Trade Call Opinion: $TSRX For a Bounce Back Over $8

BioDelivery Sciences Primed To Grab Its Share Of The $1.5 Billion Opioid Market - Seeking Alpha

BioDelivery Sciences Primed To Grab Its Share Of The $1.5 Billion Opioid Market - Seeking Alpha

I bought BioDelivery Sciences (BDSI) on Bullish Chart: Solid Small Cap Spec Investment.

I bought BioDelivery Sciences (BDSI) on Bullish Chart: Solid Small Cap Spec Investment.

GTx Pharma Showing Bullish Chart Before Upcoming June Catalyst Data Release

GTx Pharma Showing Bullish Chart Before Upcoming June Catalyst Data Release

I bought Antares @ $3.95, I see a move to $4.35 short term

I bought Antares @ $3.95, I see a move to $4.35 short term

Significant Near-Term Top-Line Data Catalyst And Platform Technology Should Rally Insmed -- Trefis

Significant Near-Term Top-Line Data Catalyst And Platform Technology Should Rally Insmed -- Trefis

Insmed: Top-Line Data Should Rally Stock | Investing.com

Insmed: Top-Line Data Should Rally Stock | Investing.com

Significant Near-Term Top-Line Data Catalyst And Platform Technology Should Propel Insmed - Seeking Alpha

Significant Near-Term Top-Line Data Catalyst And Platform Technology Should Propel Insmed - Seeking Alpha

Near-Term Catalysts And High Insider Ownership Make GTx An Attractive Buy - Seeking Alpha

Near-Term Catalysts And High Insider Ownership Make GTx An Attractive Buy - Seeking Alpha

GTx pursues three drug studies; shares rise - Proactiveinvestors (NA)

GTx pursues three drug studies; shares rise - Proactiveinvestors (NA)